Filtered By:
Drug: Avastin
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 30 results found since Jan 2013.
Recurrent Glioblastoma: A Review of the Treatment Options
Cancers (Basel). 2023 Aug 26;15(17):4279. doi: 10.3390/cancers15174279.ABSTRACTGlioblastoma is a disease with a poor prognosis. Multiple efforts have been made to improve the long-term outcome, but the 5-year survival rate is still 5-10%. Recurrence of the disease is the usual way of progression. In this situation, there is no standard treatment. Different treatment options can be considered. Among them would be reoperation or reirradiation. There are different studies that have assessed the impact on survival and the selection of patients who may benefit most from these strategies. Chemotherapy treatments have also been c...
Source: Hand Surgery - September 9, 2023 Category: Surgery Authors: Maria Angeles Vaz-Salgado Mar ía Villamayor V íctor Albarrán V íctor Alía Pilar Sotoca Jes ús Chamorro Diana Rosero Ana M Barrill Mercedes Mart ín Eva Fernandez Jos é Antonio Gutierrez Luis Mariano Rojas-Medina Luis Ley Source Type: research
Advances in immunotherapy for cervical cancer
Ther Adv Med Oncol. 2023 Mar 28;15:17588359231163836. doi: 10.1177/17588359231163836. eCollection 2023.ABSTRACTCervical cancer still represents a major public health problem, being the fourth most common cancer in incidence and mortality in women worldwide. These figures are unacceptable since cervical cancer, an human papillomavirus-related malignancy, is a largely preventable disease by means of well-established screening and vaccination programs. Patients with recurrent, persistent, or metastatic disease unsuitable for curative therapeutic approaches represent a dismal prognosis population. Until recently, these patient...
Source: Adv Data - April 3, 2023 Category: Epidemiology Authors: Juan Francisco Grau-Bejar Carmen Garcia-Duran David Garcia-Illescas Oriol Mirallas Ana Oaknin Source Type: research
Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future
Eur J Cell Biol. 2022 Dec 17;102(1):151284. doi: 10.1016/j.ejcb.2022.151284. Online ahead of print.ABSTRACTHepatocellular carcinoma (HCC) is the most common type of primary hepatic cancer and is among the major causes of mortality due to cancer. Due to the lack of efficient conventional therapeutic options for this cancer, particularly in advanced cases, novel treatments including immunotherapy have been considered. However, despite the encouraging clinical outcomes after implementing these innovative approaches, such as oncolytic viruses (OVs), adoptive cell therapies (ACT), immune checkpoint blockades (ICBs), and cancer ...
Source: European Journal of Cell Biology - December 30, 2022 Category: Cytology Authors: Neda Minaei Roya Ramezankhani Atena Tamimi Abbas Piryaei Ali Zarrabi Amir Reza Aref Ebrahim Mostafavi Massoud Vosough Source Type: research
Highlighting novel targets in immunotherapy for liver cancer
Expert Rev Gastroenterol Hepatol. 2022 Nov 20. doi: 10.1080/17474124.2022.2150841. Online ahead of print.ABSTRACTINTRODUCTION: : Alterations to the hepatic immune microenvironment can play a key role in the development and progression of cancer. This is especially true in the liver due to its evolutionarily conserved immunotolerant state. The presence of chronic inflammation can facilitate the development and progression of hepatocellular carcinoma (HCC) by disrupting the hepatic immune microenvironment. Recently, the addition of the immunotherapy atezolizumab (PD-L1 inhibitor) with bevacizumab (VEGF inhibitor) became the ...
Source: Expert Review of Gastroenterology and Hepatology - November 21, 2022 Category: Gastroenterology Authors: Samantha M Ruff Alexander H Shannon Joal D Beane Timothy M Pawlik Source Type: research
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide
CONCLUSIONS: The addition of SITOIGANAP/GM-CSF/cyclophosphamide to bevacizumab and an anti-PD-1 monoclonal antibody resulted in a significant survival benefit compared to historic control values in rGBM with minimal toxicity compared to current therapy.PMID:35837107 | PMC:PMC9273968 | DOI:10.3389/fonc.2022.934638
Source: Cancer Control - July 15, 2022 Category: Cancer & Oncology Authors: Daniela A Bota Thomas H Taylor Naomi Lomeli Xiao-Tang Kong Beverly D Fu Axel H Sch önthal Samuel Singer Deborah T Blumenthal Frank M Senecal Helena Linardou Evangelos Rokas Dimitris G Antoniou Virgil E J C Schijns Thomas C Chen Joseph Elliot Apostolos St Source Type: research
Updates on systemic therapy for cervical cancer
Indian J Med Res. 2021 Aug;154(2):293-302. doi: 10.4103/ijmr.IJMR_4454_20.ABSTRACTCervical cancer is one of the most common cancers in the world both in terms of incidence and mortality, more so important in low- and middle-income countries. Surgery and radiotherapy remain the backbone of treatment for non-metastatic cervical cancer, with significant improvement in survival provided by addition of chemotherapy to radiotherapy. Survival as well as quality of life is improved by chemotherapy in metastatic disease. Platinum-based chemotherapy with/without bevacizumab is the mainstay of treatment for metastatic disease and has...
Source: Indian J Med Res - March 17, 2022 Category: Research Authors: Paul Gopu Febin Antony Sunu Cyriac Katherine Karakasis Amit M Oza Source Type: research
